Oculis Holding AG Ordinary shares
OCSStock
$12.61−26.66%52W
Market Cap$928.00M
P/E—
Div yield—
Beta0.22
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-46.89%
Price vs S&P 500 (4W)13.99%
VGM Score23.59
Market Capitalization$928.00M
Earnings Surprise History
Q1 26-0.61est. -0.52
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.33
4.33
4.38
4.38
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OCSOculis Holding AG Ordinary shares | — | — | D | $12.61 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Oculis Holding AG is a biopharmaceutical company developing topical treatments and disease-modifying therapies for ophthalmological conditions. Its pipeline includes OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and related neuro-ophthalmological disorders. The company's candidates target prevalent eye conditions including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.